scholarly journals Pretreatment with sedative-hypnotics, but not with nondepolarizing muscle relaxants, attenuates alfentanil-induced muscle rigidity

1994 ◽  
Vol 6 (6) ◽  
pp. 473-480 ◽  
Author(s):  
Theodore J. Sanford ◽  
Matthew B. Weinger ◽  
N.Ty Smith ◽  
James L. Benthuysen ◽  
Norman Head ◽  
...  
1995 ◽  
Vol 39 (4) ◽  
pp. 246
Author(s):  
THEODORE J. SANFORD ◽  
MATTHEW B. WEINGER ◽  
N. TY SMITH ◽  
JAMES L. BENTHUYSEN ◽  
NORMAN HEAD ◽  
...  

2020 ◽  
pp. 1-3
Author(s):  
Kyu Nam Kim ◽  
Dong Won Kim ◽  
Kyu Nam Kim ◽  
Jung Eun Sun ◽  
Ji Hee Chang ◽  
...  

Masseter muscle rigidity can be seen following administration of opioids, succinylcholine, and nondepolarizing muscle relaxants. We report a case of a 56-year-old male patient in a “Cannot Intubate Cannot Ventilate Situation” due to masseter muscle rigidity after initiating monitored anaesthesia care (MAC) with remifentanil and propofol using target-controlled infusion in procedural cardiology. For rapid effect and equilibrium between plasma-concentration and effect site-concentration using target-controlled infusion, remifentanil overdose is possible during the induction period of MAC. Moreover, the presence of propofol could result in a significantly greater remifentanil concentration. To manage masseter muscle rigidity, muscle relaxants and emergent ventilation systems should be prepared to secure airway maintenance. In addition, alternative airway management devices and techniques should be on hand even if no airway difficulties are expected.


2009 ◽  
Author(s):  
Idoris Cordero Escobar ◽  
Javier Espinaco Vald��s ◽  
Angela R Gutierrez Rojas ◽  
Nicolas Parisi L��pez ◽  
Rosa E Jimenez

2007 ◽  
Author(s):  
I Cordero Escobar ◽  
J Espinaco Vald��s ◽  
AR Gutierrez Rojas ◽  
RE Jimenez Paneca ◽  
N Parisi L��pez

1998 ◽  
Vol 86 (Supplement) ◽  
pp. 457S
Author(s):  
S. Hashimoto ◽  
O. Shibata ◽  
A. Tsuda ◽  
S. Iwanaga ◽  
T. Makita ◽  
...  

2007 ◽  
Vol 85 (8) ◽  
pp. 774-782 ◽  
Author(s):  
S.B. Bhatt ◽  
A. Amann ◽  
V. Nigrovic

Nondepolarizing muscle relaxants (MRs) display an inverse onset–potency relationship, that is, less potent MRs display a more rapid onset. We have conducted the current investigation to estimate the impact of variable pharmacokinetic or pharmacodynamic properties of the MRs on potency and onset time, and on the onset–potency relationship. Using a model of neuromuscular transmission, we changed either the affinity of MRs for the postsynaptic receptors or the pharmacokinetic properties of the MRs. The elimination rate constant, k10, which defines the systemic clearance, was assigned one of 9 values and the transport rate constant, k12, one of 5 values. The transport rate constant into the effect compartment was constant (ke1 = 0.2 min–1). Only one parameter was altered at a time. With constant pharmacokinetics, a 100-fold decrease in affinity caused a proportional decrease in potency, but little change (0.02 min) in onset time. With constant affinity, increasing the clearance from 1 to 250 mL·kg–1·min–1 shortened the onset time from 7.2 to 0.7 min and decreased the potency 12-fold. In a double logarithmic plot, the onset–potency relationship was linear. Lesser affinities produce a nearly parallel rightward shift of the regression lines. The inverse onset–potency relationship may be explained by the pharmacokinetic factors producing changes in both the potency and onset times.


Sign in / Sign up

Export Citation Format

Share Document